Building on its longstanding commitment to the endocrinology community, the IBSA USA team recently returned from ENDO 2025, the Endocrine Society’s signature annual meeting. Held July 12-15 in San Francisco, California, the conference brought together more than 7,000 thousand endocrinologists, researchers, and healthcare professionals from around the world to discuss the latest research and clinical advances in hormone health.
“ENDO remains an important touchpoint for IBSA USA to connect with healthcare providers and demonstrate the Company’s ongoing focus on addressing unmet needs in thyroid disease management,” said Michael Scully, Head of Commercial Operations for IBSA USA. “This meeting provided an invaluable opportunity to engage directly with the endocrine community and share the significant strides IBSA is making in advancing patient care through our unique therapies for thyroid disease.”
IBSA USA at ENDO 2025: Advancing the Dialogue on Thyroid Health
Addressing the Symptom Gap in Hypothyroidism
A key highlight of IBSA USA’s participation was the sponsorship of an informational workshop focused on an often-overlooked clinical challenge in hypothyroidism care—persistent symptoms in patients despite achieving normal TSH levels with treatment.
The workshop, titled “Beyond the Numbers: Unmasking the Symptom Gap in Hypothyroidism,” featured expert insights from Dr. Rosemarie Lajara, MD, FACE, an endocrinologist at Southern Endocrinology & Diabetes Associates in Plano, TX.
During the session, attendees explored:
- Comprehensive strategies to recognize patients experiencing persistent symptoms
- Potential factors that contribute to persistent symptoms
- Differences in treatment formulations
- Interactive patient case discussion
The session drew strong attendance from clinicians eager to enhance their ability to manage this aspect of hypothyroid treatment.
Engaging with the Endocrinology Community
In addition to the program, IBSA USA exhibited its portfolio of products to treat hypothyroidism. At the IBSA USA booth, healthcare practitioners had the opportunity to meet with representatives to learn more about the Company’s treatment options and IBSA’s mission to deliver advanced therapies to enhance patient care.
ENDO 2025 continues to serve as a premier forum for scientific exchange and clinical education in endocrinology. For IBSA USA, the event reaffirmed its focus on advancing therapeutic solutions and collaborating with the medical community to address unmet needs in thyroid health.